Research graph
References from Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study). Local targets link to admitted publications; unresolved targets remain external evidence.
A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents
10.3389/fendo.2024.1440456 · 2024 · External reference
11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050
10.1016/s2213-8587(25)00299-2 · 2026 · External reference
The multifaceted role of metformin in type 2 diabetes: mechanisms, clinical evidence, and future directions
10.1007/s42399-025-02206-6 · 2026 · External reference
Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
10.3389/fendo.2017.00006 · 2017 · External reference
Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment
2025 · External reference
Semaglutide: a comprehensive review of its pharmacology, clinical applications, and future therapeutic potential
10.22270/jddt.v15i12.7452 · 2025 · External reference
A review on semaglutide: an oral glucagon-like peptide 1 receptor agonist in management of type 2 diabetes mellitus
10.1007/s13300-020-00894-y · 2020 · External reference
Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-Week, Open-Label, randomized clinical trial
10.2337/dc17-0417 · 2018 · External reference
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
10.1016/s2213-8587(17)30092-x · 2017 · External reference
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
10.1016/s2213-8587(17)30013-x · 2017 · External reference
Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: <scp>A</scp> systematic review and mixed‐treatment comparison analysis
10.1111/dom.12849 · 2017 · External reference
Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
10.3389/fphar.2018.00576 · 2018 · External reference
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
10.1016/s2213-8587(18)30024-x · 2018 · External reference
10.1016/s2213-8587(17)30085-2
10.1016/s2213-8587(17)30085-2 · 2017 · External reference
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial
10.1210/jc.2018-00070 · 2018 · External reference
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
10.1016/s2213-8587(19)30311-0 · 2019 · External reference
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
10.1016/s2213-8587(19)30066-x · 2019 · External reference
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
10.1016/j.diabet.2019.101117 · 2020 · External reference
SUSTAIN clinical trial programme: efficacy and safety of semaglutide
2025 · External reference
998-P: efficacy and safety of Semaglutide by baseline BMI in SUSTAIN 1-5 and 7
10.2337/db19-998-p · 2019 · External reference
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity
10.1001/jama.2021.3224 · 2021 · External reference
Once-weekly semaglutide in adults with overweight or obesity
10.1056/nejmoa2032183 · 2021 · External reference
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
10.1056/nejmoa1607141 · 2016 · External reference
Pharmacovigilance of semaglutide: a descriptive analysis of WHO-VigiAccess reports
10.1097/md.0000000000048811 · 2026 · External reference
Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system
10.3389/fpubh.2022.996179 · 2022 · External reference
